OTCMKTS:NEVPF Abliva AB (publ) (NEVPF) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 06/27/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About Abliva AB (publ) Stock (OTCMKTS:NEVPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Abliva AB (publ) alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0352-Week Range$0.01▼$0.04VolumeN/AAverage Volume4,445 shsMarket Capitalization$11.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Abliva AB (publ) is a Swedish life science company focused on the discovery and development of innovative treatments for mitochondrial dysfunction, aiming to restore cellular energy production in patients with rare metabolic and neurodegenerative disorders. The company’s lead clinical asset, KL1333, is a novel mitochondrial modulator designed to enhance cellular respiration and improve metabolic function in primary mitochondrial disease and related indications. Abliva leverages proprietary metabolic profiling and translational biomarkers within its research platform to support strategic collaborations and licensing partnerships, advancing its mission to address significant unmet medical needs in mitochondrial medicine.AI Generated. May Contain Errors. Read More Receive NEVPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address NEVPF Stock News HeadlinesPharming announces public cash offer to shareholders of Abliva ABDecember 16, 2024 | markets.businessinsider.comStillfront Group publ AB (SFRG)July 27, 2024 | investing.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.July 3 at 2:00 AM | Crypto 101 Media (Ad)Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial DiseaseJuly 19, 2024 | markets.businessinsider.comAbliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024May 13, 2024 | finance.yahoo.comProbi ABMarch 20, 2024 | barrons.comIVSXF Investor AB (publ)January 9, 2024 | seekingalpha.comInterfox Resources publ AB (IFOX)October 2, 2023 | investing.comSee More Headlines NEVPF Stock Analysis - Frequently Asked Questions How have NEVPF shares performed this year? Abliva AB (publ)'s stock was trading at $0.0360 on January 1st, 2025. Since then, NEVPF stock has decreased by 22.2% and is now trading at $0.0280. How do I buy shares of Abliva AB (publ)? Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NEVPF CIKN/A Webwww.neurovive.com Phone(646) 275-6220Fax46-4-688-883-48Employees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-117.92% Return on Assets-102.44% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual Sales$10 thousand Price / Sales1,128.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book1.40Miscellaneous Outstanding Shares403,010,000Free FloatN/AMarket Cap$11.28 million OptionableNot Optionable Beta-1.18 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (OTCMKTS:NEVPF) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abliva AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Abliva AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
